At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
Adderall ® Immediate Release +1 moredrug
Likely dose
Adderall ® Immediate Release 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
In Brief
A Phase 4 clinical trial evaluating Adderall ® Immediate Release and Adderall XR ® for Attention Deficit Hyperactivity Disorder. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartAug 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedMay 2, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.2 years ago
Interventions
Adderall ® Immediate Releasedrug
Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
Adderall XR ®drug
Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.